Compression of hands and feet to prevent nerve damage from chemotherapy
Tests compression of hands and feet in people having chemotherapy for breast or colorectal cancer.
Plain-language title generated from the registry record
Registry title: Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy
Key facts
- Where
- Jönköping, SwedenSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with breast, rectal or colon cancer who are about to start taxane or oxaliplatin chemotherapy. It tests whether compression of hands and feet prevents nerve damage.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Breast cancer planned for taxane treatment before or after surgery. Rectal cancer planned for total neoadjuvant treatment with oxaliplatin. Colorectal cancer planned for adjuvant chemotherapy with oxaliplatin. No distant metastases.
- Earlier treatment
- No earlier chemotherapy that can damage nerves. No earlier oxaliplatin treatment before surgery for the colorectal group. Planned taxane or oxaliplatin treatment must last 8 to 26 weeks.
Main reasons for not taking part
- Distant metastases
- Clear nerve damage (peripheral neuropathy) already present
- Current lymphoedema in the limbs needing compression therapy
- Ongoing pregnancy
- Compression or cold therapy of hands or feet planned during the chemotherapy
Read by machine on 9 November 2026.
Where in Sweden
- Linköping UniversityJönköping, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Jönköping County
- Trial code
- NCT07464769
- Record updated
- 11 March 2026
- Original description
Population Cohort 1 Taxane: Breast cancer patients; (neo-)adjuvant treatment Cohort 2 Oxaliplatin: Colorectal cancer patients; (neo-)adjuvant treatment Study design Multicentre, unblinded randomised controlled study Study rationale Chemotherapy-induced peripheral neuropathy is a dose-limiting side effect during treatment and cause persistent impairment and worsening of quality of life in cancer survivors.Read full original descriptionShow less
A Randomized Controlled Study of Compression Therapy of Hands and Feet for the Prevention of Taxane- or Oxaliplatin-induced Peripheral Neuropathy
Population Cohort 1 Taxane: Breast cancer patients; (neo-)adjuvant treatment Cohort 2 Oxaliplatin: Colorectal cancer patients; (neo-)adjuvant treatment Study design Multicentre, unblinded randomised controlled study Study rationale Chemotherapy-induced peripheral neuropathy is a dose-limiting side effect during treatment and cause persistent impairment and worsening of quality of life in cancer survivors.
Compression therapy could be a plausible preventive intervention, although practice changing studies are lacking.
Aims To investigate if compression therapy of the hands and feet can reduce the prevalence of both acute and persistent CIPN symptoms caused by taxanes or oxaliplatin. Furthermore, to investigate if compression therapy impact the level of taxane or oxaliplatin dose reductions.
Endpoints Primary endpoint
* The difference in the occurrence of sensory chemotherapy-induced peripheral neuropathy (CIPN) Selected secondary endpoints * Key secondary endpoint: Difference in relative dose intensity of taxane respectively oxaliplatin. * The difference in the occurrence of motor and autonomic chemotherapy-induced peripheral neuropathy (CIPN). * Difference in occurrence of persistent patient-reported CIPN symptoms 1, 3 and 5 years after start of neurotoxic chemotherapy (EORTC CIPN20) * Health-related quality of life at baseline and after 1, 3, 5 years (EORTC QLQ C30) Exploratory endpoints * Prevalence of autonomic neurotoxicity after neurotoxic treatment, defined as increase of prevalence from baseline to one year after treatment.
Substudy
• Development of pharmacogenetic risk prediction models of acute respectively persistent taxane induced peripheral neuropathy.
Sample size Randomisation 1:1, per site Taxane cohort 268 breast cancer patients, stratification on taxane type Oxaliplatin cohort 90 colorectal cancer patients, stratification on length of treatment Follow-up Patient-reported CIPN symptoms during treatment and at time point up to 5 years post-treatment.
Inclusion: o Scheduled neurotoxic treatment in any of the following settings: Taxane cohort; Breast cancer patients planned for either neoadjuvant or adjuvant taxane treatment Oxaliplatin cohort; Rectal cancer patients planned for total neoadjuvant treatment including oxaliplatin; Colorectal cancer patients planned for adjuvant chemotherapy including oxaliplatin, without prior neoadjuvant oxaliplatin treatment; Understand written and oral Swedish.
Exclusion: Previous neurotoxic chemotherapy* treatment; Current lymphoedema in limbs requiring compression therapy; Planned compression or cryotherapy of hands and/or feet during taxane or oxaliplatin; Taxanes (docetaxel, paclitaxel, nabpaclitaxel), platinum components (carboplatin, oxaplatin, cisplatin), vinca-alkaloids (vincristine, vinblastine, vinorelbine, eribulin), bortezomid, thalidomide, antibody drug conjugate including vedotin or emtansine; Any psychiatric disorder or health disorder that causes an inability to make an informed consent to participate; Distant metastases; Any manifest clinically significant peripheral neuropathy according to treating physician; Ongoing pregnancy; Planned taxane or oxaliplatin treatment shorter than 8 weeks or longer than 26 weeks.